These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25604509)

  • 1. Two-stage designs in bioequivalence trials.
    Schütz H
    Eur J Clin Pharmacol; 2015 Mar; 71(3):271-81. PubMed ID: 25604509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the upper sample size limit in two-stage bioequivalence designs.
    Karalis V
    Int J Pharm; 2013 Nov; 456(1):87-94. PubMed ID: 23954235
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-stage designs versus European scaled average designs in bioequivalence studies for highly variable drugs: Which to choose?
    Molins E; Cobo E; Ocaña J
    Stat Med; 2017 Dec; 36(30):4777-4788. PubMed ID: 28853164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of group sequential and fixed sample size designs for bioequivalence trials with highly variable drugs.
    Knahl SIE; Lang B; Fleischer F; Kieser M
    Eur J Clin Pharmacol; 2018 May; 74(5):549-559. PubMed ID: 29362819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-stage designs for cross-over bioequivalence trials.
    Kieser M; Rauch G
    Stat Med; 2015 Jul; 34(16):2403-16. PubMed ID: 25809815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modifications of sequential designs in bioequivalence trials.
    Zheng C; Zhao L; Wang J
    Pharm Stat; 2015; 14(3):180-8. PubMed ID: 25663282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. On the statistical model of the two-stage designs in bioequivalence assessment.
    Karalis V; Macheras P
    J Pharm Pharmacol; 2014 Jan; 66(1):48-52. PubMed ID: 24175961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal adaptive sequential designs for crossover bioequivalence studies.
    Xu J; Audet C; DiLiberti CE; Hauck WW; Montague TH; Parr AF; Potvin D; Schuirmann DJ
    Pharm Stat; 2016; 15(1):15-27. PubMed ID: 26538182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential design approaches for bioequivalence studies with crossover designs.
    Potvin D; DiLiberti CE; Hauck WW; Parr AF; Schuirmann DJ; Smith RA
    Pharm Stat; 2008; 7(4):245-62. PubMed ID: 17710740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and inference for 3-stage bioequivalence testing with serial sampling data.
    Yan F; Zhu H; Liu J; Jiang L; Huang X
    Pharm Stat; 2018 Sep; 17(5):458-476. PubMed ID: 29726096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Study Design on Sample Size in Studies Intended to Evaluate Bioequivalence of Inhaled Short-Acting β-Agonist Formulations.
    Zeng Y; Singh S; Wang K; Ahrens RC
    J Clin Pharmacol; 2018 Apr; 58(4):457-465. PubMed ID: 29281130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Additional results for 'Sequential design approaches for bioequivalence studies with crossover designs'.
    Montague TH; Potvin D; Diliberti CE; Hauck WW; Parr AF; Schuirmann DJ
    Pharm Stat; 2012; 11(1):8-13. PubMed ID: 21308974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pilot and Repeat Trials as Development Tools Associated with Demonstration of Bioequivalence.
    Fuglsang A
    AAPS J; 2015 May; 17(3):678-83. PubMed ID: 25732246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adaptive designs for noninferiority trials.
    Gao P; Liu L; Mehta C
    Biom J; 2013 May; 55(3):310-21. PubMed ID: 23494872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlling the type I error rate in two-stage sequential adaptive designs when testing for average bioequivalence.
    Maurer W; Jones B; Chen Y
    Stat Med; 2018 May; 37(10):1587-1607. PubMed ID: 29462835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blinded sample size re-estimation in crossover bioequivalence trials.
    Golkowski D; Friede T; Kieser M
    Pharm Stat; 2014; 13(3):157-62. PubMed ID: 24715672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential bioequivalence trial designs with increased power and controlled type I error rates.
    Fuglsang A
    AAPS J; 2013 Jul; 15(3):659-61. PubMed ID: 23543603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Group sequential extensions of a standard bioequivalence testing procedure.
    Gould AL
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):57-86. PubMed ID: 8576845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflation of Type I Error in the Evaluation of Scaled Average Bioequivalence, and a Method for its Control.
    Labes D; Schütz H
    Pharm Res; 2016 Nov; 33(11):2805-14. PubMed ID: 27480875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.